Zylox-Tonbridge Medical Technology Future Growth
Future criteria checks 5/6
Zylox-Tonbridge Medical Technology is forecast to grow earnings and revenue by 79.3% and 23.5% per annum respectively. EPS is expected to grow by 79.1% per annum. Return on equity is forecast to be 8.2% in 3 years.
Key information
79.3%
Earnings growth rate
79.1%
EPS growth rate
| Medical Equipment earnings growth | 35.3% |
| Revenue growth rate | 23.5% |
| Future return on equity | 8.2% |
| Analyst coverage | Low |
| Last updated | 10 Apr 2024 |
Recent future growth updates
Recent updates
Zylox-Tonbridge Medical Technology Co., Ltd.'s (HKG:2190) Shares May Have Run Too Fast Too Soon
Apr 23
Zylox-Tonbridge Medical Technology Co., Ltd. (HKG:2190) Shares Could Be 48% Below Their Intrinsic Value Estimate
Jan 18Does This Valuation Of Zylox-Tonbridge Medical Technology Co., Ltd. (HKG:2190) Imply Investors Are Overpaying?
Sep 21There's Reason For Concern Over Zylox-Tonbridge Medical Technology Co., Ltd.'s (HKG:2190) Price
Aug 03We're Not Very Worried About Zylox-Tonbridge Medical Technology's (HKG:2190) Cash Burn Rate
Jun 30Is Zylox-Tonbridge Medical Technology Co., Ltd. (HKG:2190) Trading At A 45% Discount?
Mar 08We're Not Very Worried About Zylox-Tonbridge Medical Technology's (HKG:2190) Cash Burn Rate
Jan 19Here's Why We're Not Too Worried About Zylox-Tonbridge Medical Technology's (HKG:2190) Cash Burn Situation
Jul 06We're Hopeful That Zylox-Tonbridge Medical Technology (HKG:2190) Will Use Its Cash Wisely
Jan 27Here's Why We're Not At All Concerned With Zylox-Tonbridge Medical Technology's (HKG:2190) Cash Burn Situation
Oct 05Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 1,396 | 287 | 29 | N/A | 3 |
| 12/31/2025 | 1,087 | 161 | -64 | N/A | 4 |
| 12/31/2024 | 764 | 72 | -146 | N/A | 4 |
| 12/31/2023 | 528 | -79 | N/A | N/A | N/A |
| 9/30/2023 | 470 | -101 | N/A | N/A | N/A |
| 6/30/2023 | 411 | -124 | -250 | -60 | N/A |
| 3/31/2023 | 373 | -119 | -244 | -76 | N/A |
| 12/31/2022 | 334 | -114 | -237 | -91 | N/A |
| 9/30/2022 | 297 | -135 | -242 | -107 | N/A |
| 6/30/2022 | 259 | -155 | -247 | -122 | N/A |
| 3/31/2022 | 219 | -178 | -227 | -119 | N/A |
| 12/31/2021 | 178 | -200 | -206 | -116 | N/A |
| 9/30/2021 | 137 | -168 | -186 | -107 | N/A |
| 6/30/2021 | 97 | -135 | -166 | -98 | N/A |
| 3/31/2021 | 62 | -118 | -147 | -90 | N/A |
| 12/31/2020 | 28 | -100 | -127 | -82 | N/A |
| 12/31/2019 | 5 | -67 | -95 | -53 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 2190 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).
Earnings vs Market: 2190 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 2190 is expected to become profitable in the next 3 years.
Revenue vs Market: 2190's revenue (23.5% per year) is forecast to grow faster than the Hong Kong market (8.1% per year).
High Growth Revenue: 2190's revenue (23.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 2190's Return on Equity is forecast to be low in 3 years time (8.2%).